Metabolic effects and clinical outcomes of olanzapine in schizophrenia: A systematic review and meta-analysis
2024

Effects of Olanzapine on Metabolism in Schizophrenia

Sample size: 1839 publication Evidence: moderate

Author Information

Author(s): Jin Weifeng, Chen Shuzi, Li Dan, Chen Qing, Zhu Mengyuan, Wang Mengxia, Fu Xiaomei, Lin Ping

Primary Institution: Shanghai Mental Health Center, China

Hypothesis

What are the metabolic changes and clinical outcomes of patients with schizophrenia treated with olanzapine?

Conclusion

Adjusting the dosage of olanzapine based on blood concentration can maximize efficacy while minimizing metabolic side effects.

Supporting Evidence

  • Patients receiving olanzapine had significant weight gain.
  • Clinical response improved with higher plasma concentrations of olanzapine.
  • Weight gain was rapid in the first few weeks of treatment.
  • Changes in cholesterol levels were not significant during treatment.
  • Individual responses to olanzapine dosage varied among patients.

Takeaway

This study found that olanzapine can help people with schizophrenia feel better, but it might also make them gain weight.

Methodology

A systematic review and meta-analysis of clinical trials using databases like PubMed and Cochrane Library to assess metabolic changes and clinical responses.

Potential Biases

Some included studies had a lower quality, particularly in random sequence generation and allocation concealment.

Limitations

The study included a limited number of studies with varying quality, and the heterogeneity of the population may affect outcomes.

Participant Demographics

1839 participants, 1058 male and 781 female, aged 15 to 55 years.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI: 0.06–0.44

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/j.heliyon.2024.e40424

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication